145903-31-7

Basic information

• Product Name: 2,3,4,5-Tetrahydro-7-methoxy-1,4-benzothiazepine
• Synonyms: 1,4-Benzothiazepine, 2,3,4,5-tetrahydro-7-methoxy-;7-methoxy- 2,3,4,5-tetrahydro-1,4-Benzothiazepine;2,3,4,5-Tetrahydro-7-methoxy-1,4-benzothiazepine;2,3,4,5-Tetrahydro-7-methoxy-1,4-benzothiazepine Discontinued;7-Methoxy-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine
• CAS NO: 145903-31-7
• Molecular Formula: C₁₀H₁₃NOS
• Molecular Weight: 195.28
• Product Categories: Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds
• Mol File: 145903-31-7.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 336.9 °C at 760 mmHg
• Flash Point: 157.5 °C
• Appearance: /
• Density: 1.125 g/cm³
• Vapor Pressure: 0.000109mmHg at 25°C
• Refractive Index: 1.566
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 2,3,4,5-Tetrahydro-7-methoxy-1,4-benzothiazepine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3,4,5-Tetrahydro-7-methoxy-1,4-benzothiazepine(145903-31-7)
• EPA Substance Registry System: 2,3,4,5-Tetrahydro-7-methoxy-1,4-benzothiazepine(145903-31-7)

Safety Data

• Hazardous Substances Data: 145903-31-7(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 145903-31-7 differently. You can refer to the following data:
1. A tetrahydrobenzothiazepine compound for treating or reducing muscle fatigue.
2. A tetrahydrobenzothiazepine compound for treating or reducing muscle fatigue. An intermediate of S-107, the ryanodine receptor-based Ca2+-channel stabilizer.

InChI:InChI=1/C10H13NOS/c1-12-9-2-3-10-8(6-9)7-11-4-5-13-10/h2-3,6,11H,4-5,7H2,1H3

Upstream product

• 55114-90-4 methyl 5-methoxy-2-sulfanyl-benzoate 
• 16807-37-7 5-methoxy-2-sulfanyl-benzoic acid 
• 104795-62-2 methyl-2-((N,N-dimethylcarbamoyl)thio)-5-methoxybenzoate 
• 104795-61-1 methyl 2-((dimethylcarbamothioyl)oxy)-5-methoxybenzoate 
• 2905-82-0 methyl 5-methoxy-2-hydroxybenzoate 
• 13739-36-1 β-(4-methoxyphenylmercapto)propionic acid 
• 13735-11-0 6-methoxy-2,3-dihydro-4H-thiochromen-4-one 
• 1186400-76-9 benzyl-2-(4-methoxyphenylthio)ethylcarbamate 
• 696-63-9 4-Methoxybenzenethiol 
• 36155-36-9 2-<(4-methoxyphenyl)thio>-1-aminoethane 
• 1186400-77-0 benzyl 7-methoxy-2,3-dihydrobenzo[f][1,4]-thiazepine-4(5H)-carboxylate 
• 689-98-5 chloroethylamine 
• 6705-03-9 2-Amino-5-methoxybenzoic acid 
• 594-09-2 trimethylphosphane 

Downstream Products

• 1467605-60-2 methyl-3-((7-methoxy-2,3-dihydrobenzo[f][1,4]thiazepin-4(5H)-yl)methyl)benzoate 
• 927871-76-9 S107 

Relevant articles and documents

Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor

Ziresovir (RO-0529, AK0529) is reported here for the first time as a promising respiratory syncytial virus (RSV) fusion (F) protein inhibitor that currently is in phase 2 clinical trials. This article describes the process of RO-0529 as a potent, selective, and orally bioavailable RSV F protein inhibitor and highlights the in vitro and in vivo anti-RSV activities and pharmacokinetics in animal species. RO-0529 demonstrates single-digit nM EC50 potency against laboratory strains, as well as clinical isolates of RSV in cellular assays, and more than one log viral load reduction in BALB/c mouse model of RSV viral infection. RO-0529 was proven to be a specific RSV F protein inhibitor by identification of drug resistant mutations of D486N, D489V, and D489Y in RSV F protein and the inhibition of RSV F protein-induced cell-cell fusion in cellular assays.

Agents for treating disorders involving modulation of ryanodine receptors

The present invention relates to 1,4-benzothiazepine derivatives and their use to treat conditions, disorders and diseases associated with ryanodine receptors (RyRs) that regulate calcium channel functioning in cells. The invention also discloses pharmaceutical compositions comprising the compounds and uses thereof to treat diseases and conditions associated with RyRs, in particular cardiac, musculoskeletal and central nervous system (CNS) disorders.

PROCESS FOR PREPARING BENZOTHIAZEPINES FROM GAMMA-AMINOALKYLBENZENES

The invention provides a process for preparing a 2,3,4,5-tetrahydro[1,4]benzothiazepine of formula: by reacting a [2-(acylaminoethyl)thio]arene of formula with an aldehyde or a multimer thereof, and with an acid. The invention also provides for first reac